Boston AI startup forecasts breast cancer risk from mammograms before tumors form
TL;DR
Boston-based Clairity, led by radiologist Dr. Connie Lehman, has FDA authorization to use an AI system that analyzes mammograms to predict a woman's risk of developing breast cancer, enabling preventive actions and tailored screening. Trained on over 400,000 mammograms with five-year follow-ups and tested on 77,000 images, the deep neural network outperformed traditional risk calculators and could expand to younger ages and more diverse populations, though the model remains a 'black box' in parts; investors include ACE Global Equity and Santé Ventures as Boston's health-tech scene grows.
Topics:healthtechnology#ai-in-healthcare#boston-tech-scene#breast-cancer#fda-approval#mammography#technology
- Boston AI startup can predict risk of breast cancer before tumors appear The Boston Globe
- AI in screening mammography, UW participates in multi-institutional trial The Badger Herald
- First Patient Receives FDA-Authorized Clairity Breast GlobeNewswire
- Large Mammography Study Shows AI-Aided DBT Bolsters Cancer Detection Without Increasing Recall Rate diagnosticimaging.com
- First Clairity Breast cancer risk score given at BIDMC AuntMinnie
Want the full story? Read the original reporting
Read on The Boston Globe